Arcutis To Host ZORYVE Cream 0.15% FDA Approval Call With Key Opinion Leader On Monday, July 29, 2024 at 8:30am ET

7/22/24 8:06:50 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ARQT alert in real time by email

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring a leading dermatology and immune-mediated skin disease expert to discuss the unmet need and current treatment landscape for individuals with mild to moderate atopic dermatitis (AD). The event will highlight the differentiating features of and commercialization plans for ZORYVE® (roflumilast) cream 0.15%, which recently received FDA approval for the treatment of AD in adults and children down to age 6.

Details for the event are as follows:

Monday, July 29, 2024

8:30am ET

To register, click here.

Additional information may be accessed at the "Events" section of the Company's website.

Get the next $ARQT alert in real time by email

Date	Price Target	Rating	Analyst
8/28/2024	$15.00	Buy	Jefferies
1/3/2024	$4.00 → $8.00	Neutral → Buy	Mizuho
10/26/2023	$57.00 → $4.00	Buy → Neutral	Mizuho
10/13/2023	$32.00 → $6.00	Buy → Neutral	Goldman
9/7/2022	$46.00	Buy	Needham
3/17/2022	$45.00	Buy	Goldman
3/2/2022	$35.00 → $37.00	Overweight	Morgan Stanley
11/19/2021	$50.00 → $35.00	Overweight	Morgan Stanley

Arcutis To Host ZORYVE Cream 0.15% FDA Approval Call With Key Opinion Leader On Monday, July 29, 2024 at 8:30am ET

Chat with this insight

Recent Analyst Ratings for $ARQT

$ARQT Financials

Live finance-specific insights

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

$ARQT Market Insights

Live Market Insights

Arcutis Submits Supplemental NDA For ZORYVE Foam To The FDA For The Treatment Of Scalp And Body Psoriasis In Adults And Adolescents Ages 12 And Over

Arcutis To Host ZORYVE Cream 0.15% FDA Approval Call With Key Opinion Leader On Monday, July 29, 2024 at 8:30am ET

FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years

$ARQT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Officer Matsuda Masaru was granted 4,875 shares and sold $17,190 worth of shares (1,775 units at $9.68), increasing direct ownership by 2% to 181,373 units (SEC Form 4)

Officer Burnett Patrick converted options into 18,477 shares and sold $712,621 worth of shares (69,226 units at $10.29), decreasing direct ownership by 28% to 128,669 units (SEC Form 4)

Director Curran Terrie sold $94,238 worth of shares (8,687 units at $10.85), decreasing direct ownership by 46% to 10,139 units (SEC Form 4)

$ARQT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

$ARQT Leadership Updates

Live Leadership Updates

$ARQT Press Releases

Fastest customizable press release news feed in the world

$ARQT FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

Arcutis Announces Leadership Transition

Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary

Arcutis' ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

$ARQT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jefferies initiated coverage on Arcutis Biotherapeutics with a new price target

Arcutis Biotherapeutics upgraded by Mizuho with a new price target

Arcutis Biotherapeutics downgraded by Mizuho with a new price target

$ARQT SEC Filings

$ARQT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 144 filed by Arcutis Biotherapeutics Inc.

SEC Form 144 filed by Arcutis Biotherapeutics Inc.

SEC Form 144 filed by Arcutis Biotherapeutics Inc.

Heron Patrick J bought $199,994 worth of shares (21,052 units at $9.50) (SEC Form 4)

Watanabe Todd Franklin exercised 59,525 shares at a strike of $1.68 and bought $9,334 worth of shares (1,463 units at $6.38), increasing direct ownership by 13% to 515,145 units (SEC Form 4)

Recent Analyst Ratings for
$ARQT

$ARQT
Financials

$ARQT
Market Insights

$ARQT
Insider Trading

$ARQT
Large Ownership Changes

$ARQT
Leadership Updates

$ARQT
Press Releases

$ARQT
FDA approvals

$ARQT
Analyst Ratings

$ARQT
SEC Filings

$ARQT
Insider Purchases